LENG1 Inhibitors
LENG1 inhibitors encompass a diverse array of compounds that can indirectly lead to the inhibition of LENG1 through various cellular and biochemical pathways. Histone deacetylase inhibitors, such as Trichostatin A and Vorinostat, can modify chromatin structure and gene expression patterns, which may result in the downregulation of proteins that stabilize or activate LENG1. This alteration in expression can lead to a functional inhibition of LENG1 as the protein's regulatory environment is disrupted. Proteasome inhibitors like MG132 and Bortezomib prevent the degradation of proteins, which can lead to the accumulation of negative regulators of LENG1, thus impeding its activity. By inhibiting the degradation pathway, these compounds indirectly contribute to the functional inhibition of LENG1.
Furthermore, inhibitors targeting signal transduction pathways, including LY294002, Wortmannin, Rapamycin, PD98059, U0126, SB203580, and SP600125, manipulate various kinases and phosphorylation events that are crucial for the regulation of LENG1 activity. LY294002 and Wortmannin, for instance, inhibit the PI3K/AKT pathway, which can decrease the post-translational modifications necessary for LENG1's activity. Rapamycin inhibits mTOR, potentially reducing protein synthesis of factors required for LENG1 function. PD98059 and U0126 impair the MAPK/ERK pathway, which could reduce downstream regulatory effects on LENG1. SB203580 and SP600125 target the p38 MAP kinase and JNK pathways, respectively, which might lead to a decrease in the phosphorylation of proteins that regulate LENG1, thereby inhibiting its functional activity. Staurosporine, a broad-spectrum kinase inhibitor, may inhibit a range of kinases involved in the regulation of LENG1, further contributing to the inhibition of the protein's function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Histone deacetylase inhibitor that increases acetylation levels, leading to alterations in chromatin structure and gene expression. By changing the expression profile of genes, Trichostatin A indirectly inhibits LENG1 by possibly reducing the expression of factors that stabilize LENG1 or are required for its activity. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Histone deacetylase inhibitor similar to Trichostatin A, Vorinostat can alter gene expression patterns, potentially decreasing the expression of proteins that interact with LENG1, thereby inhibiting its functional activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that prevents the degradation of ubiquitinated proteins, potentially leading to the accumulation of proteins that negatively regulate LENG1 or its associated factors, resulting in the inhibition of LENG1 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Another proteasome inhibitor, Bortezomib, can lead to an increase in cellular proteins that may include negative regulators of LENG1, thus indirectly inhibiting LENG1 functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that impedes the PI3K/AKT pathway, possibly causing a reduction in the post-translational modifications of LENG1 that are necessary for its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that can lead to a decrease in protein synthesis, including proteins that are essential for the functional activity of LENG1, thereby indirectly inhibiting LENG1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that impairs the MAPK/ERK pathway, potentially leading to the reduced activity of downstream targets involved in the functional regulation of LENG1. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Another MEK inhibitor, U0126, can indirectly inhibit LENG1 by inhibiting ERK phosphorylation and activation, which may be necessary for LENG1's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAP kinase inhibitor that could impede the phosphorylation of substrates involved in the regulation of LENG1 activity, thereby indirectly inhibiting LENG1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that may suppress the JNK signaling pathway, leading to a decrease in the functional activity of proteins that regulate LENG1. | ||||||